Buphenyl Therapy for Byler's Disease
NCT01784718 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2013-02-06
Summary
This is a single patient compassionate use protocol to determine whether Buphenyl (4-phenylbutyrate) will improve the poor bile flow associated with Byler Disease.
Conditions
- Byler Disease
Interventions
- DRUG
-
Buphenyl
Sponsors & Collaborators
-
University of Pittsburgh
lead OTHER
Eligibility
- Min Age
- 1 Year
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis
NCT01173159 ·Status: COMPLETED ·Phase: NA
-
Study of Bile Acids in Patients With Peroxisomal Disorders
NCT00004442 ·Status: TERMINATED ·Phase: NA
-
Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
NCT02929303 ·Status: APPROVED_FOR_MARKETING
-
Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
NCT02328768 ·Status: APPROVED_FOR_MARKETING
-
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
NCT03471143 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Fibrates in Pediatric Cholestasis
NCT03586674 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease
NCT00004315 ·Status: UNKNOWN ·Phase: PHASE2
-
Compassionate Use of Omegaven IV Fat Emulsion
NCT00816348 ·Status: TERMINATED ·Phase: PHASE2
-
Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children
NCT04542473 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Role of Fenofibrate in Neonatal Jaundice
NCT06451900 ·Status: COMPLETED ·Phase: PHASE4
-
Compassionate Use of Omegaven in Children
NCT02370251 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
NCT06121375 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
NCT01473524 ·Status: COMPLETED ·Phase: PHASE3
-
Total Parenteral Nutrition-Associated Liver Disease
NCT00031135 ·Status: TERMINATED ·Phase: PHASE2
-
Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
NCT02534077 ·Status: APPROVED_FOR_MARKETING
-
GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis
NCT01589523 ·Status: COMPLETED ·Phase: PHASE3
-
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
NCT00007020 ·Status: COMPLETED ·Phase: PHASE3
-
Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis
NCT03312140 ·Status: COMPLETED ·Phase: NA
-
Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis
NCT01115582 ·Status: COMPLETED ·Phase: PHASE3
-
Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease
NCT00862446 ·Status: COMPLETED ·Phase: PHASE4
-
Intraductal Liposomal Bupivacaine for Chronic Pancreatitis
NCT04611958 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Omegaven as Alternative Parenteral Fat Nutrition
NCT03662282 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
NCT01934777 ·Status: COMPLETED ·Phase: PHASE3
-
Cholestanol in Humans
NCT00018694 ·Status: WITHDRAWN ·Phase: NA
-
The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 2)
NCT07303868 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4